5 ways to like a Pfizer-AZ merger
This article was originally published in Scrip
There's been a lot of ink spilled on why Pfizer buying AstraZeneca would be a terrible idea. It would strike a body blow to UK science. It would cost people their jobs at both firms. It would deprive US national coffers of their rightful tax revenues. It would deflect attention from the business at hand just when focusing on R&D is critically urgent. The combined group would simply be an even huger entity facing declining sales (two wrongs don't make a right).
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.